Table 5.

Prostate cancer risk and stage among statin users stratified by the cumulative quantity of medication purchases

Prostate cancer riskLength of the observed time period
4 y
5 y
6 y
7 y
8 y
n*OR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)
Overall
    1-1,460 DDD1,695/1,5991.06 (0.99-1.14)1,293/1,2311.05 (0.97-1.14)912/8851.03 (0.94-1.14)464/4830.96 (0.84-1.09)427/4360.98 (0.76-1.11)
    ≥1,461 DDD171/1411.21 (0.96-1.54)180/1451.24 (0.99-1.55)180/1461.23 (0.98-1.54)128/1021.26 (0.97-1.65)103/831.24 (0.95-1.62)
Localized
    1-1,460 DDD620/5691.09 (0.97-1.23)456/4001.14 (0.99-1.30)333/2921.14 (0.97-1.34)144/1381.04 (0.82-1.32)132/1281.03 (0.79-1.34)
    ≥1,461 DDD73/571.27 (0.87-1.25)73/571.29 (0.90-1.84)66/521.26 (0.86-1.83)36/341.07 (0.64-1.80)31/281.10 (0.72-1.91)
Advanced
    1-1,460 DDD123/1760.70 (0.55-0.89)85/1250.68 (0.51-0.90)54/760.71 (0.49-1.02)26/430.61 (0.36-1.03)18/280.65 (0.33-1.02)
    ≥1,461 DDD10/130.78 (0.34-1.80)9/130.70 (0.30-1.66)11/130.82 (0.36-1.85)6/80.73 (0.24-2.23)3/40.71 (0.22-2.39)
  • NOTE: Study population of all newly diagnosed prostate cancer cases in Finland in 1995 to 2002 and their individually matched controls.

  • * Number of case-control pairs discordant to medication usage: Case: user-control: nonuser/Case: nonuser-control: user.

  • Adjusted for age, usage of diuretics, calcium-channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, metformin, sulfonylureas, and human insulin.

  • The cumulative quantity of statins purchased during the observed time period; 1,460 DDD used as a cut point as it corresponds to 4 y of usage if a person used regularly 1 DDD/d.